Target intelligence / Profile preview

T-cell receptor beta variable 10 (TRBV10)

Target
TRBV10
Molecular classification
Receptor
01

Overview

T-cell receptor beta variable 10 (TRBV10), also known as T-cell receptor Vβ10, is a germline-encoded variable segment of the T-cell receptor (TCR) beta chain. It is expressed on a specific subset of αβ T lymphocytes, representing approximately 1% to 5% of the peripheral T-cell repertoire in humans. TRBV10 plays a critical role in adaptive immunity by participating in the formation of the TCR heterodimer, which recognizes peptide-major histocompatibility complex (pMHC) complexes on antigen-presenting cells to initiate T-cell activation and downstream signaling.\n\nIn oncology, TRBV10-expressing T cells are highly prevalent among tumor-infiltrating lymphocytes (TILs) across various cancer types. This makes TRBV10 an attractive therapeutic target for precision immunotherapy, allowing for the selective activation of tumor-reactive T-cell subsets without causing systemic, indiscriminate T-cell activation. The lead therapeutic candidate targeting this receptor is invikafusp alfa (STAR0602), a first-in-class bispecific dual T-cell agonist that selectively binds to Vβ6 and Vβ10 TCRs while delivering a co-stimulatory signal via fused interleukin-2 (IL-2) in cis. This interaction drives the selective expansion of clonally diverse, effector memory Vβ6/Vβ10 T cells, promoting potent anti-tumor activity in patients with advanced, checkpoint-resistant solid tumors.

Other names
T-cell receptor Vβ10T-cell receptor Vbeta10TCR Vβ10TCR Vbeta10T-cell receptor beta variable 10-1T-cell receptor beta variable 10-2T-cell receptor beta variable 10-3TRBV10-1TRBV10-2TRBV10-3TCRBV10S1TCRBV10S2TCRBV10S3
02

Mechanism of action

T-cell receptor Vβ6/Vβ10 agonist

03

Biological functions

Immune responseSignal transduction
04

Disease associations

CancerInfectionInflammation
05

Safety considerations

Cytokine release syndrome (CRS)Off-target immune activationAutoimmunityT-cell depletion
06

Interacting drugs

07

Biomarkers

TCR Vβ10 expressionVβ6/Vβ10 T-cell expansionTumor mutational burden-high (TMB-H)Microsatellite instability-high (MSI-H)

Beyond the preview

Go deeper on T-cell receptor beta variable 10 (TRBV10).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on T-cell receptor beta variable 10 (TRBV10).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call